{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:03:44Z","timestamp":1761948224850,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pcd.2017.01.003","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T18:48:10Z","timestamp":1485197290000},"page":"254-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antidiabetic medications use trends in an Andalusian region from 2001 to 2014"],"prefix":"10.1016","volume":"11","author":[{"given":"Roc\u00edo","family":"L\u00f3pez-Sep\u00falveda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-817X","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"Garc\u00eda Lirola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Esp\u00ednola Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Mar\u00eda","family":"Jurado Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvadora","family":"Mart\u00edn Sances","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Anaya Ord\u00f3\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Cabeza Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1999","series-title":"Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus","author":"World Health Organization","key":"10.1016\/j.pcd.2017.01.003_bib0005"},{"key":"10.1016\/j.pcd.2017.01.003_bib0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.pcd.2017.01.003_bib0015","unstructured":"World Health Organization, WHO | Global Status Report on NCDs, (n.d.). http:\/\/www.who.int\/chp\/ncd_global_status_report\/en\/ (Accessed 20 November 2015)."},{"key":"10.1016\/j.pcd.2017.01.003_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","article-title":"Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es study","volume":"55","author":"Soriguer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.pcd.2017.01.003_bib0025","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.recesp.2013.09.031","article-title":"Prevalence of obesity, diabetes and other cardiovascular risk factors in Andalusia (Southern Spain). Comparison with national prevalence data. The Di@bet.es study","volume":"67","author":"Vald\u00e9s","year":"2014","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.pcd.2017.01.003_bib0030","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.pcd.2015.03.009","article-title":"Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time","volume":"9","author":"Torre","year":"2015","journal-title":"Prim. Care Diabetes"},{"key":"10.1016\/j.pcd.2017.01.003_bib0035","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/dc06-2499","article-title":"How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists","volume":"30","author":"Grant","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2017.01.003_bib0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diabres.2011.05.004","article-title":"Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy\u2019s Lombardy Region: a large population-based study","volume":"93","author":"Baviera","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.pcd.2017.01.003_bib0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.diabres.2014.12.007","article-title":"Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study","volume":"108","author":"Rafaniello","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.pcd.2017.01.003_bib0050","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/dc13-2289","article-title":"Use of antidiabetic drugs in the U.S., 2003\u20132012","volume":"37","author":"Hampp","year":"2014","journal-title":"Diabetes Care"},{"year":"2012","series-title":"Guidelines for ATC Classification and DDD Assignment 2013","author":"WHO Collaborating Centre for Drug Statistics Methodology","key":"10.1016\/j.pcd.2017.01.003_bib0055"},{"year":"2015","series-title":"Type 2 Diabetes | Guidance and Guidelines |","author":"NICE","key":"10.1016\/j.pcd.2017.01.003_bib0060"},{"key":"10.1016\/j.pcd.2017.01.003_bib0065","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2017.01.003_bib0070","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.2337\/diacare.25.12.2244","article-title":"Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes","volume":"25","author":"Johnson","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2017.01.003_bib0075","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/1060028014558289","article-title":"Pharmacologic treatment of type 2 diabetes: oral medications","volume":"49","author":"Tran","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pcd.2017.01.003_bib0080","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2017.01.003_bib0085","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch. Intern. Med."},{"year":"2011","series-title":"Update on Ongoing European Review of Pioglitazone-containing Medicines. Suspension of Use of These Medicines in France While Europe-wide Review Continues","author":"European Medicines Agency","key":"10.1016\/j.pcd.2017.01.003_bib0090"},{"year":"2013","series-title":"Osakidetza, Diabetes-Gu\u00edas de Pr\u00e1ctica Cl\u00ednica-Profesionales-Osakidetza-Euskadi.eus","author":"DTATOVEL","key":"10.1016\/j.pcd.2017.01.003_bib0095"},{"key":"10.1016\/j.pcd.2017.01.003_bib0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4093\/dmj.2015.39.5.373","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies","volume":"39","author":"Son","year":"2015","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.pcd.2017.01.003_bib0105","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2017.01.003_bib0110","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2017.01.003_bib0115","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pcd.2017.01.003_bib0120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2017.01.003_bib0125","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/archinte.168.19.2088","article-title":"National trends in treatment of type 2 diabetes mellitus, 1994\u20132007","volume":"168","author":"Alexander","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcd.2017.01.003_bib0130","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00125-006-0331-3","article-title":"Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels","volume":"49","author":"Melander","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.pcd.2017.01.003_bib0135","series-title":"Utilizaci\u00f3n de medicamentos antidiab\u00e9ticos en Espa\u00f1a durante el periodo 2000\u20132014","first-page":"1","author":"Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios","year":"2015"},{"key":"10.1016\/j.pcd.2017.01.003_bib0140","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/pds.1802","article-title":"Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis","volume":"18","author":"Filion","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"year":"2011","series-title":"Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update, (n.d.)","author":"Bennett","key":"10.1016\/j.pcd.2017.01.003_bib0145"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991817300037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991817300037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:56:12Z","timestamp":1761695772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991817300037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1751991817300037"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2017.01.003","relation":{},"ISSN":["1751-9918"],"issn-type":[{"type":"print","value":"1751-9918"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidiabetic medications use trends in an Andalusian region from 2001 to 2014","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2017.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}